{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T07:56:12Z","timestamp":1790668572137,"version":"4.1.0"},"reference-count":102,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,5,14]],"date-time":"2022-05-14T00:00:00Z","timestamp":1652486400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Hematology, Transfusion and Cell Therapy"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1016\/j.htct.2022.04.006","type":"journal-article","created":{"date-parts":[[2022,5,26]],"date-time":"2022-05-26T01:33:46Z","timestamp":1653528826000},"page":"582-594","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Diagnosis and treatment of systemic mastocytosis in Brazil: Recommendations of a multidisciplinary expert panel"],"prefix":"10.1016","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9707-0579","authenticated-orcid":false,"given":"Elvira D. Rodrigues Pereira","family":"Velloso","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1031-8659","authenticated-orcid":false,"given":"Ge\u00f3rgia A.","family":"Padulla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8779-834X","authenticated-orcid":false,"given":"Ana Maria M\u00f3sca","family":"de Cerqueira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriana Martins","family":"de Sousa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex Freire","family":"Sandes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4258-289X","authenticated-orcid":false,"given":"Fabiola","family":"Traina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6637-3588","authenticated-orcid":false,"given":"Fernanda Salles","family":"Seguro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1337-7635","authenticated-orcid":false,"given":"Frederico Lisboa","family":"Nogueira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grazielly de F\u00e1tima","family":"Pereira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9738-8210","authenticated-orcid":false,"given":"Jos\u00e9 Laerte","family":"Boechat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7975-0805","authenticated-orcid":false,"given":"Katia Borgia Barbosa","family":"Pagnano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luan Lima","family":"Marchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8652-3619","authenticated-orcid":false,"given":"Luis Felipe","family":"Ensina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7059-4068","authenticated-orcid":false,"given":"Mara","family":"Giavina-Bianchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9882-5200","authenticated-orcid":false,"given":"Marcelo Vivolo","family":"Aun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0503-5179","authenticated-orcid":false,"given":"Rosana C\u00e2mara","family":"Agondi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8573-9493","authenticated-orcid":false,"given":"Fabio Pires de Souza","family":"Santos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1034-7580","authenticated-orcid":false,"given":"Pedro","family":"Giavina-Bianchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.htct.2022.04.006_bib0001","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1158\/0008-5472.CAN-16-2234","article-title":"Advances in the classification and treatment of mastocytosis: current status and outlook toward the future","volume":"77","author":"Valent","year":"2017","journal-title":"Cancer Res."},{"issue":"3","key":"10.1016\/j.htct.2022.04.006_bib0002","doi-asserted-by":"crossref","first-page":"e164","DOI":"10.1016\/S2352-3026(20)30432-4","article-title":"Improving prognostication and management of systemic mastocytosis","volume":"8","author":"Soverini","year":"2021","journal-title":"Lancet Haematol mar\u00e7o de"},{"key":"10.1016\/j.htct.2022.04.006_bib0003","unstructured":"OCEBM Levels of Evidence Working Group*. OCEBM Levels of Evidence Working Group*. \u201cThe Oxford 2011 Levels of Evidence\u201d. [Internet]. Oxford Centre for Evidence-Based Medicine. Available in: http:\/\/www.cebm.net\/index.aspx?o=5653"},{"issue":"4","key":"10.1016\/j.htct.2022.04.006_bib0004","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1002\/ajh.26118","article-title":"Systemic mastocytosis in adults: 2021 update on diagnosis, risk stratification and management","volume":"96","author":"Pardanani","year":"2021","journal-title":"Am J Hematol."},{"issue":"11","key":"10.1016\/j.htct.2022.04.006_bib0005","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1182\/blood-2016-09-731893","article-title":"Mastocytosis: 2016 updated WHO classification and novel emerging treatment concepts","volume":"129","author":"Valent","year":"2017","journal-title":"Blood."},{"issue":"1","key":"10.1016\/j.htct.2022.04.006_bib0006","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1590\/abd1806-4841.20141847","article-title":"Adult mastocytosis: a review of the Santo Ant\u00f3nio Hospital \u2019s experience and an evaluation of World Health Organization criteria for the diagnosis of systemic disease","volume":"89","author":"Fernandes","year":"2014","journal-title":"An Bras Dermatol"},{"issue":"11","key":"10.1016\/j.htct.2022.04.006_bib0007","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1016\/S0145-2126(02)00041-3","article-title":"Detection of c-kit point mutation Asp-816\u00a0\u2192\u00a0Val in microdissected pooled single mast cells and leukemic cells in a patient with systemic mastocytosis and concomitant chronic myelomonocytic leukemia","volume":"26","author":"Sotlar","year":"2002","journal-title":"Leuk Res"},{"issue":"6","key":"10.1016\/j.htct.2022.04.006_bib0008","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1038\/leu.2015.24","article-title":"KIT mutation analysis in mast cell neoplasms: recommendations of the European competence network on mastocytosis","volume":"29","author":"Arock","year":"2015","journal-title":"Leukemia."},{"issue":"2","key":"10.1016\/j.htct.2022.04.006_bib0009","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.iac.2014.01.003","article-title":"Epidemiology, prognosis, and risk factors in mastocytosis","volume":"34","author":"Brockow","year":"2014","journal-title":"Immunol Allergy Clin N Am."},{"issue":"3","key":"10.1016\/j.htct.2022.04.006_bib0010","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1111\/bjd.13567","article-title":"Paediatric mastocytosis: a systematic review of 1747 cases","volume":"172","author":"M\u00e9ni","year":"2015","journal-title":"Br J Dermatol"},{"issue":"3","key":"10.1016\/j.htct.2022.04.006_bib0011","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/S0889-8588(05)70295-1","article-title":"Mastocytosis and the skin","volume":"14","author":"Soter","year":"2000","journal-title":"Hematol Oncol Clin N Am"},{"issue":"3","key":"10.1016\/j.htct.2022.04.006_bib0012","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.iac.2018.04.001","article-title":"Cutaneous mastocytosis in adults and children: new classification and prognostic factors","volume":"38","author":"Matito","year":"2018","journal-title":"Immunol Allergy Clin N Am"},{"issue":"7","key":"10.1016\/j.htct.2022.04.006_bib0013","doi-asserted-by":"crossref","DOI":"10.3390\/jcm10071474","article-title":"Cutaneous mastocytosis in childhood-update from the literature","volume":"10","author":"Sandru","year":"2021","journal-title":"J Clin Med"},{"issue":"1","key":"10.1016\/j.htct.2022.04.006_bib0014","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.jaci.2015.08.034","article-title":"Cutaneous manifestations in patients with mastocytosis: consensus report of the european competence network on mastocytosis; the american academy of allergy, asthma & immunology; and the European Academy of Allergology and Clinical Immunology","volume":"137","author":"Hartmann","year":"2016","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"10.1016\/j.htct.2022.04.006_bib0015","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1111\/ajd.13443","article-title":"Cutaneous mastocytosis: a dermatological perspective","volume":"62","author":"Raimondo","year":"2021","journal-title":"Australas J Dermatol"},{"issue":"3","key":"10.1016\/j.htct.2022.04.006_bib0016","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.iac.2018.04.011","article-title":"Mast cell mediators of significance in clinical practice in mastocytosis","volume":"38","author":"Butterfield","year":"2018","journal-title":"Immunol Allergy Clin N Am"},{"issue":"1","key":"10.1016\/j.htct.2022.04.006_bib0017","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1159\/000501079","article-title":"Why the 20%\u00a0+\u00a02 tryptase formula is a diagnostic gold standard for severe systemic mast cell activation and mast cell activation syndrome","volume":"180","author":"Valent","year":"2019","journal-title":"Int Arch Allergy Immunol"},{"issue":"3","key":"10.1016\/j.htct.2022.04.006_bib0018","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/S0889-8588(05)70300-2","article-title":"Serum tryptase and the laboratory diagnosis of systemic mastocytosis","volume":"14","author":"Schwartz","year":"2000","journal-title":"Hematol Oncol Clin N Am"},{"issue":"2","key":"10.1016\/j.htct.2022.04.006_bib0019","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1159\/000059404","article-title":"Serum tryptase levels in patients with mastocytosis: correlation with mast cell burden and implication for defining the category of disease","volume":"128","author":"Sperr","year":"2002","journal-title":"Int Arch Allergy Immunol"},{"issue":"02","key":"10.1016\/j.htct.2022.04.006_bib0020","doi-asserted-by":"crossref","first-page":"51","DOI":"10.23822\/EurAnnACI.1764-1489.133","article-title":"Recommendations for the use of tryptase in the diagnosis of anaphylaxis and clonal mastcell disorders","volume":"52","author":"Platzgummer","year":"2020","journal-title":"Eur Ann Allergy Clin Immunol"},{"issue":"12","key":"10.1016\/j.htct.2022.04.006_bib0021","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20122976","article-title":"Multidisciplinary challenges in mastocytosis and how to address with personalized medicine approaches","volume":"20","author":"Valent","year":"2019","journal-title":"Int J Mol Sci"},{"issue":"2","key":"10.1016\/j.htct.2022.04.006_bib0022","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1309\/2EWQKN00PG02JKY0","article-title":"Bone marrow biopsies for the diagnosis of systemic mastocytosis: is one biopsy sufficient?","volume":"121","author":"Butterfield","year":"2004","journal-title":"Am J Clin Pathol"},{"issue":"3","key":"10.1016\/j.htct.2022.04.006_bib0023","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1309\/AJCPSGQ71GJQQACL","article-title":"Morphologically occult systemic mastocytosis in bone marrow: clinicopathologic features and an algorithmic approach to diagnosis","volume":"144","author":"Reichard","year":"2015","journal-title":"Am J Clin Pathol"},{"issue":"9","key":"10.1016\/j.htct.2022.04.006_bib0024","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1038\/modpathol.2011.84","article-title":"Evaluation of the WHO criteria for the classification of patients with mastocytosis","volume":"24","author":"S\u00e1nchez-Mu\u00f1oz","year":"2011","journal-title":"Mod Pathol"},{"issue":"3","key":"10.1016\/j.htct.2022.04.006_bib0025","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1155\/1998\/341340","article-title":"Immunophenotypic characterization of human bone marrow mast cells. A flow cytometric study of normal and pathological bone marrow samples","volume":"16","author":"Escribano","year":"1998","journal-title":"Anal Cell Pathol J Eur Soc Anal Cell Pathol"},{"issue":"4","key":"10.1016\/j.htct.2022.04.006_bib0026","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1038\/modpathol.2011.192","article-title":"Immunophenotyping in systemic mastocytosis diagnosis: \u2018CD25 positive\u2019 alone is more informative than the \u2018CD25 and\/or CD2\u2019 WHO criterion","volume":"25","author":"Morgado","year":"2012","journal-title":"Mod Pathol"},{"issue":"3","key":"10.1016\/j.htct.2022.04.006_bib0027","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.iac.2018.04.005","article-title":"Kit mutations: new insights and diagnostic value","volume":"38","author":"Falchi","year":"2018","journal-title":"Immunol Allergy Clin N Am"},{"issue":"1","key":"10.1016\/j.htct.2022.04.006_bib0028","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/s00277-013-1964-1","article-title":"The KIT D816V expressed allele burden for diagnosis and disease monitoring of systemic mastocytosis","volume":"93","author":"Erben","year":"2014","journal-title":"Ann Hematol"},{"issue":"3","key":"10.1016\/j.htct.2022.04.006_bib0029","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1038\/jid.2009.281","article-title":"Pediatric mastocytosis is a clonal disease associated with D816V and other activating c-KIT mutations","volume":"130","author":"Bodemer","year":"2010","journal-title":"J Investig Dermatol"},{"issue":"12","key":"10.1016\/j.htct.2022.04.006_bib0030","doi-asserted-by":"crossref","first-page":"e126","DOI":"10.1200\/JCO.2011.38.9973","article-title":"Complete response after imatinib mesylate therapy in a patient with well-differentiated systemic mastocytosis","volume":"30","author":"\u00c1lvarez-Twose","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.htct.2022.04.006_bib0031","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.leukres.2018.12.010","article-title":"Molecular response to imatinib in KIT F522C-mutated systemic mastocytosis","volume":"77","author":"Broderick","year":"2019","journal-title":"Leuk Res"},{"issue":"3","key":"10.1016\/j.htct.2022.04.006_bib0032","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/j.jaci.2009.05.003","article-title":"Prognosis in adult indolent systemic mastocytosis: a long-term study of the Spanish Network on Mastocytosis in a series of 145 patients","volume":"124","author":"Escribano","year":"2009","journal-title":"J Allergy Clin Immunol"},{"issue":"6","key":"10.1016\/j.htct.2022.04.006_bib0033","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1111\/all.12409","article-title":"The KIT D816V allele burden predicts survival in patients with mastocytosis and correlates with the WHO type of the disease","volume":"69","author":"Hoermann","year":"2014","journal-title":"Allergy"},{"issue":"2","key":"10.1016\/j.htct.2022.04.006_bib0034","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.jmgm.2004.04.003","article-title":"Molecular basis of the constitutive activity and STI571 resistance of Asp816Val mutant KIT receptor tyrosine kinase","volume":"23","author":"Foster","year":"2004","journal-title":"J Mol Graph Model"},{"issue":"9","key":"10.1016\/j.htct.2022.04.006_bib0035","doi-asserted-by":"crossref","first-page":"3093","DOI":"10.1182\/blood-2003-05-1627","article-title":"CHIC2 deletion, a surrogate for FIP1L1-PDGFRA fusion, occurs in systemic mastocytosis associated with eosinophilia and predicts response to imatinib mesylate therapy","volume":"102","author":"Pardanani","year":"2003","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.htct.2022.04.006_bib0036","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21113987","article-title":"Recent advances in the molecular biology of systemic mastocytosis: implications for diagnosis, prognosis, and therapy","volume":"21","author":"Martelli","year":"2020","journal-title":"Int J Mol Sci"},{"issue":"3","key":"10.1016\/j.htct.2022.04.006_bib0037","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/S0002-9440(10)63870-9","article-title":"One-step detection of c-kit point mutations using peptide nucleic acid-mediated polymerase chain reaction clamping and hybridization probes","volume":"162","author":"Sotlar","year":"2003","journal-title":"Am J Pathol"},{"key":"10.1016\/j.htct.2022.04.006_bib0038","doi-asserted-by":"crossref","DOI":"10.1016\/j.blre.2020.100693","article-title":"Non-hematologic diagnosis of systemic mastocytosis: collaboration of radiology and pathology","volume":"45","author":"Ozturk","year":"2021","journal-title":"Blood Rev"},{"issue":"9","key":"10.1016\/j.htct.2022.04.006_bib0039","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1007\/s00259-016-3415-4","article-title":"The EANM practice guidelines for bone scintigraphy","volume":"43","author":"Van den Wyngaert","year":"2016","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"4","key":"10.1016\/j.htct.2022.04.006_bib0040","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1309\/2880LF7Q6XK3HA3Q","article-title":"Are gastrointestinal mucosal mast cells increased in patients with systemic mastocytosis?","volume":"122","author":"Siegert","year":"2004","journal-title":"Am J Clin Pathol"},{"issue":"3","key":"10.1016\/j.htct.2022.04.006_bib0041","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/S0889-8588(05)70298-7","article-title":"Gastrointestinal abnormalities and involvement in systemic mastocytosis","volume":"14","author":"Jensen","year":"2000","journal-title":"Hematol Oncol Clin N Am"},{"issue":"2","key":"10.1016\/j.htct.2022.04.006_bib0042","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1148\/radiology.202.2.9015059","article-title":"Systemic mastocytosis: CT and US features of abdominal manifestations","volume":"202","author":"Avila","year":"1997","journal-title":"Radiology"},{"issue":"13","key":"10.1016\/j.htct.2022.04.006_bib0043","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1007\/s00259-015-3117-3","article-title":"FDG-PET\/CT findings in systemic mastocytosis: a French multicentre study","volume":"42","author":"Djelbani-Ahmed","year":"2015","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"5","key":"10.1016\/j.htct.2022.04.006_bib0044","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.2214\/ajr.179.5.1791235","article-title":"FDG positron emission tomography in patients with systemic mastocytosis","volume":"179","author":"Zettinig","year":"2002","journal-title":"Am J Roentgenol"},{"issue":"7","key":"10.1016\/j.htct.2022.04.006_bib0045","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1097\/RLU.0000000000001207","article-title":"Extramedullary involvement of mast cell leukemia detected by 18F-FDG PET\/CT","volume":"41","author":"Fu","year":"2016","journal-title":"Clin Nucl Med"},{"issue":"23","key":"10.1016\/j.htct.2022.04.006_bib0046","doi-asserted-by":"crossref","first-page":"5727","DOI":"10.1182\/blood-2009-02-205237","article-title":"Systemic mastocytosis in 342 consecutive adults: survival studies and prognostic factors","volume":"113","author":"Lim","year":"2009","journal-title":"Blood"},{"issue":"21","key":"10.1016\/j.htct.2022.04.006_bib0047","doi-asserted-by":"crossref","first-page":"2964","DOI":"10.1182\/bloodadvances.2018026245","article-title":"Mayo alliance prognostic system for mastocytosis: clinical and hybrid clinical-molecular models","volume":"2","author":"Pardanani","year":"2018","journal-title":"Blood Adv"},{"key":"10.1016\/j.htct.2022.04.006_bib0048","unstructured":"Consensus Opinion on Allogeneic Hematopoietic Cell Transplantation in Advanced Systemic Mastocytosis | Elsevier Enhanced Reader [Internet]. [citado 20 de junho de 2021]. Available in:https:\/\/reader.elsevier.com\/reader\/sd\/pii\/S1083879116300374?token=740608063BEEC9C7929B85707F4F7682306F68E7F9460A01505605661C8047B328511DDDCC44A4826C615C8FC34CC71F&originRegion=us-east-1&originCreation=20210621004449"},{"issue":"2","key":"10.1016\/j.htct.2022.04.006_bib0049","article-title":"Mast cell activation disorders","volume":"57","author":"Giannetti","year":"2021","journal-title":"Med Kaunas Lith"},{"key":"10.1016\/j.htct.2022.04.006_bib0050","unstructured":"Andersen C.L., Kristensen T.K., Severinsen M.T., M\u00f8ller M.B., Vestergaard H., Bergmann O.J., et\u00a0al. Systemic mastocytosis a systematic review. 2012;6."},{"key":"10.1016\/j.htct.2022.04.006_bib0051","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.leukres.2019.04.001","article-title":"Relevant updates in systemic mastocytosis","volume":"81","author":"Coltoff","year":"2019","journal-title":"Leuk Res"},{"key":"10.1016\/j.htct.2022.04.006_bib0052","doi-asserted-by":"crossref","unstructured":"Brazzelli V, Grassi S, Merante S, Grasso V, Ciccocioppo R, Bossi G, et al. Narrow-band UVB phototherapy and psoralen-ultraviolet A photochemotherapy in the treatment of cutaneous mastocytosis: a study in 20 patients. Photodermatol Photoimmunol Photomed. 2016;32(5-6):238\u2013246.","DOI":"10.1111\/phpp.12248"},{"issue":"18","key":"10.1016\/j.htct.2022.04.006_bib0053","doi-asserted-by":"crossref","first-page":"3050","DOI":"10.3889\/oamjms.2019.772","article-title":"Melanoma and mastocytosis","volume":"7","author":"Vojvodic","year":"2019","journal-title":"Open Access Maced J Med Sci"},{"issue":"5","key":"10.1016\/j.htct.2022.04.006_bib0054","doi-asserted-by":"crossref","first-page":"583","DOI":"10.2340\/00015555-1788","article-title":"Increased risk of malignant melanoma in patients with systemic mastocytosis?","volume":"94","author":"H\u00e4gglund","year":"2014","journal-title":"Acta Derm Venereol"},{"issue":"1","key":"10.1016\/j.htct.2022.04.006_bib0055","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.iac.2016.08.017","article-title":"Mastocytosis and anaphylaxis","volume":"37","author":"Schuch","year":"2017","journal-title":"Immunol Allergy Clin N Am"},{"issue":"45","key":"10.1016\/j.htct.2022.04.006_bib0056","doi-asserted-by":"crossref","first-page":"6862","DOI":"10.2174\/1381612822666160928121857","article-title":"Mast cell disorders in drug hypersensitivity","volume":"22","author":"Bonadonna","year":"2017","journal-title":"Curr Pharm Des"},{"issue":"4","key":"10.1016\/j.htct.2022.04.006_bib0057","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.anai.2017.07.022","article-title":"Management around invasive procedures in mastocytosis: an update","volume":"119","author":"Hermans","year":"2017","journal-title":"Ann Allergy Asthma Immunol Off Publ Am Coll Allergy Asthma Immunol"},{"issue":"1","key":"10.1016\/j.htct.2022.04.006_bib0058","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1007\/s11882-009-0080-8","article-title":"Anaphylaxis and Mast cell disease: what is the risk?","volume":"10","author":"Akin","year":"2010","journal-title":"Curr Allergy Asthma Rep"},{"issue":"3","key":"10.1016\/j.htct.2022.04.006_bib0059","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22031454","article-title":"A challenge for allergologist: application of allergy diagnostic methods in mast cell disorders","volume":"22","author":"Romantowski","year":"2021","journal-title":"Int J Mol Sci"},{"issue":"2","key":"10.1016\/j.htct.2022.04.006_bib0060","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1111\/j.1398-9995.2007.01569.x","article-title":"Anaphylaxis in patients with mastocytosis: a study on history, clinical features and risk factors in 120 patients","volume":"63","author":"Brockow","year":"2008","journal-title":"Allergy"},{"issue":"1","key":"10.1016\/j.htct.2022.04.006_bib0061","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/S0091-6749(97)70188-X","article-title":"Hymenoptera sting anaphylaxis and urticaria pigmentosa: Clinical findings and results of venom immunotherapy in ten patients","volume":"100","author":"Fricker","year":"1997","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.htct.2022.04.006_bib0062","doi-asserted-by":"crossref","first-page":"792","DOI":"10.3389\/fimmu.2017.00792","article-title":"Insights in anaphylaxis and clonal mast cell disorders","volume":"8","author":"Gonz\u00e1lez-de-Olano","year":"2017","journal-title":"Front Immunol"},{"issue":"10","key":"10.1016\/j.htct.2022.04.006_bib0063","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1111\/all.13445","article-title":"Low frequency of acetyl salicylic acid hypersensitivity in mastocytosis: the results of a double-blind, placebo-controlled challenge study","volume":"73","author":"Hermans","year":"2018","journal-title":"Allergy"},{"issue":"6","key":"10.1016\/j.htct.2022.04.006_bib0064","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1016\/j.jaip.2019.01.059","article-title":"Anaphylaxis to quinolones in mastocytosis: Hypothesis on the mechanism","volume":"7","author":"Giavina-Bianchi","year":"2019","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"1","key":"10.1016\/j.htct.2022.04.006_bib0065","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1159\/000436969","article-title":"Management of anesthesia in adult and pediatric mastocytosis: a study of the Spanish network on mastocytosis (REMA) based on 726 anesthetic procedures","volume":"167","author":"Matito","year":"2015","journal-title":"Int Arch Allergy Immunol"},{"issue":"7","key":"10.1016\/j.htct.2022.04.006_bib0066","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1111\/all.12617","article-title":"Drug hypersensitivity in clonal mast cell disorders: ENDA\/EAACI position paper","volume":"70","author":"Bonadonna","year":"2015","journal-title":"Allergy"},{"issue":"1","key":"10.1016\/j.htct.2022.04.006_bib0067","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1111\/cea.12225","article-title":"High prevalence of anaphylaxis in patients with systemic mastocytosis \u2013 a single-centre experience","volume":"44","author":"G\u00fclen","year":"2014","journal-title":"Clin Exp Allergy"},{"issue":"4","key":"10.1016\/j.htct.2022.04.006_bib0068","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1016\/j.jaip.2019.02.002","article-title":"Mast cell activation syndrome and mastocytosis: initial treatment options and long-term management","volume":"7","author":"Castells","year":"2019","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"1","key":"10.1016\/j.htct.2022.04.006_bib0069","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1186\/s13054-015-0956-z","article-title":"Critical care management of systemic mastocytosis: when every wasp is a killer bee","volume":"19","author":"van der Weide","year":"2015","journal-title":"Crit Care"},{"issue":"1\u20132","key":"10.1016\/j.htct.2022.04.006_bib0070","doi-asserted-by":"crossref","first-page":"46","DOI":"10.20452\/pamw.2644","article-title":"Risk factors for anaphylaxis in patients with mastocytosis","volume":"125","author":"G\u00f3rska","year":"2015","journal-title":"Pol Arch Intern Med"},{"issue":"5","key":"10.1016\/j.htct.2022.04.006_bib0071","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1111\/all.14580","article-title":"Diagnosing, managing and preventing anaphylaxis: systematic review","volume":"76","author":"Silva de","year":"2021","journal-title":"Allergy"},{"issue":"1","key":"10.1016\/j.htct.2022.04.006_bib0072","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.jaip.2013.09.004","article-title":"The mastocytosis society survey on mast cell disorders: patient experiences and perceptions","volume":"2","author":"Jennings","year":"2014","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"9","key":"10.1016\/j.htct.2022.04.006_bib0073","doi-asserted-by":"crossref","first-page":"3093","DOI":"10.1016\/j.jaip.2020.05.044","article-title":"Low frequency of IgE-mediated food hypersensitivity in mastocytosis","volume":"8","author":"Jarkvist","year":"2020","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"1","key":"10.1016\/j.htct.2022.04.006_bib0074","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.semarthrit.2006.03.004","article-title":"The role of mast cells in osteoporosis","volume":"36","author":"Chiappetta","year":"2006","journal-title":"Semin Arthritis Rheum"},{"issue":"3","key":"10.1016\/j.htct.2022.04.006_bib0075","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.iac.2018.04.013","article-title":"Bone disease in mastocytosis","volume":"38","author":"Orsolini","year":"2018","journal-title":"Immunol Allergy Clin N Am"},{"issue":"4","key":"10.1016\/j.htct.2022.04.006_bib0076","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1016\/j.bone.2011.07.004","article-title":"Bone mineral density, bone turnover markers and fractures in patients with indolent systemic mastocytosis","volume":"49","author":"Rossini","year":"2011","journal-title":"Bone"},{"issue":"6","key":"10.1016\/j.htct.2022.04.006_bib0077","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1016\/j.jaci.2014.05.003","article-title":"Predictors of new fragility fractures after diagnosis of indolent systemic mastocytosis","volume":"134","author":"van der Veer","year":"2014","journal-title":"J Allergy Clin Immunol"},{"issue":"6","key":"10.1016\/j.htct.2022.04.006_bib0078","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1007\/s00223-017-0241-z","article-title":"Denosumab for the treatment of mastocytosis-related osteoporosis: a case series","volume":"100","author":"Orsolini","year":"2017","journal-title":"Calcif Tissue Int"},{"issue":"11","key":"10.1016\/j.htct.2022.04.006_bib0079","doi-asserted-by":"crossref","first-page":"1127.e1","DOI":"10.1016\/j.amjmed.2014.06.015","article-title":"Zoledronic acid in osteoporosis secondary to mastocytosis","volume":"127","author":"Rossini","year":"2014","journal-title":"Am J Med"},{"issue":"10","key":"10.1016\/j.htct.2022.04.006_bib0080","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1136\/ard.2009.124511","article-title":"Systemic mastocytosis and bone involvement in a cohort of 75 patients","volume":"69","author":"Barete","year":"2010","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"10.1016\/j.htct.2022.04.006_bib0081","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1007\/s00198-016-3539-1","article-title":"Prevalence, pathogenesis, and treatment options for mastocytosis-related osteoporosis","volume":"27","author":"Rossini","year":"2016","journal-title":"Osteoporos Int"},{"issue":"2","key":"10.1016\/j.htct.2022.04.006_bib0082","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1093\/ajcp\/aqaa183","article-title":"Mastocytosis","volume":"155","author":"Tzankov","year":"2021","journal-title":"Am J Clin Pathol"},{"issue":"2","key":"10.1016\/j.htct.2022.04.006_bib0083","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1007\/s00277-020-04323-9","article-title":"Catching the clinical and biological diversity for an appropriate therapeutic approach in systemic mastocytosis","volume":"100","author":"Mannelli","year":"2021","journal-title":"Ann Hematol"},{"issue":"2","key":"10.1016\/j.htct.2022.04.006_bib0084","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1002\/cncr.21996","article-title":"Imatinib mesylate in the treatment of systemic mastocytosis","volume":"107","author":"Droogendijk","year":"2006","journal-title":"Cancer"},{"issue":"11","key":"10.1016\/j.htct.2022.04.006_bib0085","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1016\/j.leukres.2008.12.020","article-title":"Phase II study of imatinib mesylate as therapy for patients with systemic mastocytosis","volume":"33","author":"Vega-Ruiz","year":"2009","journal-title":"Leuk Res"},{"issue":"9","key":"10.1016\/j.htct.2022.04.006_bib0086","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1016\/j.leukres.2011.05.006","article-title":"Tyrosine kinase inhibitors in the treatment of systemic mastocytosis","volume":"35","author":"Ustun","year":"2011","journal-title":"Leuk Res"},{"issue":"40","key":"10.1016\/j.htct.2022.04.006_bib0087","doi-asserted-by":"crossref","first-page":"68950","DOI":"10.18632\/oncotarget.10711","article-title":"Imatinib in systemic mastocytosis: a phase IV clinical trial in patients lacking exon 17 KIT mutations and review of the literature","volume":"8","author":"Alvarez-Twose","year":"2016","journal-title":"Oncotarget"},{"issue":"3","key":"10.1016\/j.htct.2022.04.006_bib0088","doi-asserted-by":"crossref","first-page":"433","DOI":"10.2174\/138945011794815293","article-title":"Interferon-\u03b1 treatment in systemic mastocytosis","volume":"12","author":"Weis Bjerrum","year":"2011","journal-title":"Curr Drug Targets"},{"issue":"5","key":"10.1016\/j.htct.2022.04.006_bib0089","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1016\/j.jaip.2017.05.021","article-title":"Management of mastocytosis in pregnancy: a review","volume":"5","author":"Lei","year":"2017","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"8","key":"10.1016\/j.htct.2022.04.006_bib0090","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1182\/blood-2014-12-614743","article-title":"Long-term efficacy and safety of cladribine (2-CdA) in adult patients with mastocytosis","volume":"126","author":"Barete","year":"2015","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.htct.2022.04.006_bib0091","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1002\/ajh.21561","article-title":"Cytoreductive therapy in 108 adults with systemic mastocytosis: outcome analysis and response prediction during treatment with interferon-alpha, hydroxyurea, imatinib mesylate or 2-chlorodeoxyadenosine","volume":"84","author":"Lim","year":"2009","journal-title":"Am J Hematol"},{"issue":"12","key":"10.1016\/j.htct.2022.04.006_bib0092","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.6004\/jnccn.2018.0088","article-title":"Systemic mastocytosis, version 2.2019, NCCN clinical practice guidelines in oncology","volume":"16","author":"Gotlib","year":"2018","journal-title":"J Natl Compr Canc Netw"},{"issue":"26","key":"10.1016\/j.htct.2022.04.006_bib0093","doi-asserted-by":"crossref","first-page":"2530","DOI":"10.1056\/NEJMoa1513098","article-title":"Efficacy and safety of midostaurin in advanced systemic mastocytosis","volume":"374","author":"Gotlib","year":"2016","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.htct.2022.04.006_bib0094","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1038\/leu.2017.234","article-title":"Efficacy and safety of midostaurin in patients with advanced systemic mastocytosis: 10-year median follow-up of a phase II trial","volume":"32","author":"DeAngelo","year":"2018","journal-title":"Leukemia"},{"issue":"21","key":"10.1016\/j.htct.2022.04.006_bib0095","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V116.21.316.316","article-title":"KIT inhibitor midostaurin exhibits a high rate of clinically meaningful and durable responses in advanced systemic mastocytosis: report of a fully accrued phase II trial","volume":"116","author":"Gotlib","year":"2010","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.htct.2022.04.006_bib0096","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.jaci.2020.03.044","article-title":"Midostaurin improves quality of life and mediator-related symptoms in advanced systemic mastocytosis","volume":"146","author":"Hartmann","year":"2020","journal-title":"J Allergy Clin Immunol"},{"issue":"26","key":"10.1016\/j.htct.2022.04.006_bib0097","doi-asserted-by":"crossref","first-page":"2605","DOI":"10.1056\/NEJMc1515403","article-title":"Midostaurin in advanced systemic mastocytosis","volume":"374","author":"Chandesris","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.htct.2022.04.006_bib0098","doi-asserted-by":"crossref","unstructured":"Dhillon S. Avapritinib: first approval. Drugs. 1o de mar\u00e7o de 2020;80(4):433\u20139.","DOI":"10.1007\/s40265-020-01275-2"},{"issue":"6","key":"10.1016\/j.htct.2022.04.006_bib0099","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22062983","article-title":"Response criteria in advanced systemic mastocytosis: evolution in the era of KIT inhibitors","volume":"22","author":"Shomali","year":"2021","journal-title":"Int J Mol Sci"},{"issue":"13","key":"10.1016\/j.htct.2022.04.006_bib0100","doi-asserted-by":"crossref","first-page":"2393","DOI":"10.1182\/blood-2012-09-458521","article-title":"International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) & European Competence Network on Mastocytosis (ECNM) consensus response criteria in advanced systemic mastocytosis","volume":"121","author":"Gotlib","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.htct.2022.04.006_bib0101","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaip.2021.03.041","article-title":"COVID-19 vaccination in mastocytosis: recommendations of the European Competence Network on Mastocytosis (ECNM) and American Initiative in Mast Cell Diseases (AIM)","author":"Bonadonna","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"4","key":"10.1016\/j.htct.2022.04.006_bib0102","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1111\/cea.12882","article-title":"Vaccination management in children and adults with mastocytosis","volume":"47","author":"Zanoni","year":"2017","journal-title":"Clin Exp Allergy"}],"container-title":["Hematology, Transfusion and Cell Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2531137922000803?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2531137922000803?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T13:36:56Z","timestamp":1762868216000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2531137922000803"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10]]},"references-count":102,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["S2531137922000803"],"URL":"https:\/\/doi.org\/10.1016\/j.htct.2022.04.006","relation":{},"ISSN":["2531-1379"],"issn-type":[{"value":"2531-1379","type":"print"}],"subject":[],"published":{"date-parts":[[2022,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Diagnosis and treatment of systemic mastocytosis in Brazil: Recommendations of a multidisciplinary expert panel","name":"articletitle","label":"Article Title"},{"value":"Hematology, Transfusion and Cell Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.htct.2022.04.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Associa\u00e7\u00e3o Brasileira de Hematologia, Hemoterapia e Terapia Celular. Published by Elsevier Espa\u00f1a, S.L.U.","name":"copyright","label":"Copyright"}]}}